Infection with Leishmania causes significant morbidity and mortality worldwide. The type of Leishmania species infecting the host and the immune response generated by the host determines the spectrum of clinical disease that is seen. In particular, the pattern of cytokine production from T cells is critical for protection. At present there is no vaccine for Leishmania that is easy to administer, efficacious, and cost effective. These experiments will seek to establish a vaccine regimen that is sufficient to confer long-term protective immunity following infectious challenge in mice and primates. Experiments will specifically focus on DNA, protein and recombinant viral vaccines. In addition, these studies will evaluate the cellular and molecular mechanisms by which different vaccine formulations induce long-term protective cellular immunity. Over the past year we have determined the following.? ? 1. The quality of a Th1 response differs between adenoviral and protein/ TLR ligand based vaccines.? 2. Multi-functional Th1 responses which secrete IL-2, TNF and IFN-g are correlated with protection and optimal effector cells.? 3. Effector memory Th1 responses secrete IL-2 as well as IFN-g and TNFa.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI005017-06
Application #
7592388
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2007
Total Cost
$621,788
Indirect Cost
City
State
Country
United States
Zip Code
Penberthy, W Todd; Chari, Soumya; Cole, Amy L et al. (2011) Retrocyclins and their activity against HIV-1. Cell Mol Life Sci 68:2231-42
Foulds, Kathryn E; Rotte, Masashi J; Paley, Michael A et al. (2008) IFN-gamma mediates the death of Th1 cells in a paracrine manner. J Immunol 180:842-9
Seder, Robert A; Darrah, Patricia A; Roederer, Mario (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8:247-58
Darrah, Patricia A; Patel, Dipti T; De Luca, Paula M et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13:843-50
Flynn, Barbara; Wang, Vivian; Sacks, David L et al. (2005) Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun 73:4948-54
Kirman, Joanna R; Seder, Robert A (2003) DNA vaccination: the answer to stable, protective T-cell memory? Curr Opin Immunol 15:471-6
Shah, Javeed A; Darrah, Patricia A; Ambrozak, David R et al. (2003) Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 198:281-91
Freidag, Brenda L; Mendez, Susana; Cheever, Allen W et al. (2003) Immunological and pathological evaluation of rhesus macaques infected with Leishmania major. Exp Parasitol 103:160-8
Rhee, Elizabeth G; Mendez, Susana; Shah, Javeed A et al. (2002) Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 195:1565-73
Mendez, S; Gurunathan, S; Kamhawi, S et al. (2001) The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166:5122-8